The beneficial effect of tamoxifen on serum lipoprotein-a levels: An additional anti-atherogenic property

Anticancer Research

Volumn 16, Issue 5 A, 1996, Pages 2725-2728

  Elisaf, Moses ^a   Bairaktarp, Eleni ^a   Nicolaides, Costas ^a   Fountzilas, George ^b   Tzallas, Christos ^a   Siamopoulos, Kostas ^a   Tsolas, Orestes ^a   Pavlidis, Nicholas ^a,c  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^b AHEPA UNIVERSITY HOSPITAL   (Greece)

^c UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Lipid parameters; Lipoprotein(a); Tamoxifen

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TAMOXIFEN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROGENESIS; BREAST CANCER; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ANTILIPEMIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HUMANS; LIPOPROTEIN(A); MIDDLE AGED; PROSPECTIVE STUDIES; TAMOXIFEN;

EID: 0029954947     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Lerner LJ, Jordan VC. Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture. Cancer Res 50: 4177-4189, 1990.
2. Love RR. Tamoxifen therapy in primary breast cancer: biology, efficacy, and side effects. J Clin Oncol 7: 803-815, 1989.
3. Early Breast Cancer Trialists' Collaborative Group: Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N Engl J Med 319: 1681-1692, 1988.
4. Love RR: Prospects for antiestrogen chemoprevention of breast cancer. J Natl Cancer Inst 82: 18-21, 1990.
5. Love RR, Newcomb PA, Wiebe DA, Surawicz TS, Craig Jordan V, Carbone PP, De Mets DL: Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst 82: 1327-1332, 1990.
6. Powles TJ, Hardy JR, Ashley SE, Farrington GM, Cosgrove D, Davey JB, Dowsett M, McKinna JA, Nash AG, Sinnett HD, Tillyer CR, Treleaven JG: A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer 60: 126-131, 1989.
7. Bruning PF, Bonfrer JM, Hart M, de Jong-Bakker M, Linders D, van Loon J: Tamoxifen, serum lipoproteins and cardiovascular risk. Br J Cancer 58: 497-499, 1988.
8. Bertelli G, Pronzato P, Amoroso D, Cusimano MP, Conte PF, Montagna G, Bertolini S, Rosso R: Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels. Breast Cancer Res Treat 12: 307-310, 1 988.
9. Sedlacek S: Estrogenic properties of tamoxifen on serum lipids in postmenopausal women with breast cancer (Abstract). Breast Cancer Res Treat 14: 153, 1989.
10. Bagdade JD, Wolter J, Subbaiah PV, Ryan W: Effects of tamoxifen treatment on plasma lipids and lipoprotein lipid composition. J Clin Endocrinol Metab 70: 1132-1135, 1990.
11. Schapira VD, Kumar BN, Lyman HG: Serum cholesterol reduction with tamoxifen. Breast Cancer Res Treat 17: 3-7, 1990.
12. Dnistrian MA, Schwartz KM, Greenberg JE, Smith AC, Schwartz CD: Effect of tamoxifen on serum choresterol and lipoproteins during chemohormonal therapy. Clin Chim Acta 223: 43-52, 1993.
13. Dewar JA, Horobin JM, Preece PE, Tavendale R, Tunstall-Pedoe H, Wood RA: Long term effects of tamoxifen on blood lipid values in breast cancer. BMJ 305: 225-226, 1992.
14. Love RR, Wiebe DA, Newcomb PA, Cameron L, Leventhal H, Craig Jordan V, Feyzi J. De Mets DL: Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 115: 860-864, 1991.
15. Powles JT, Tillyer RC, Jones LA, Ashley SE, Treleaven J, Davey JB, McKinna JA: Prevention of breast cancer with tamoxifen an update on the Royal Marsden Hospital pilot programme. Eur J Cancer 26: 680-684, 1990.
16. Rousser S, Walgren A: Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen. Atherosclerosis 52: 339-346, 1984
17. Ingram D: Tamoxifen use, oestrogen binding and serum lipids in postmenopausal women with breast cancer. Aust NZ J Surgery 60: 673-675, 1990.
18. Utermann G: The mysteries of lipoprotein (a). Science 246: 904-910, 1989.
19. Scanu AM, Fless GM: Lipoprotein (a): Heterogeneity and biological relevance. J Clin Invest 85: 1709-1715, 1990.
20. Rhoads GG, Dahlen G, Berg K, Morton NE, Dannenberg AL: Lp(a) lipoprotein as risk factor for myocardial infarction. JAMA 256: 2540-2544, 1986.
21. Sandkamp M, Funke H, Schulte H, Kohler E, Assman G: Lipoprotein (a) is an independent risk factor for myocardial infarction at a young age. Clin Chem 36: 20-23, 1990.
22. Seed M, Hoppichler F, Reaveley D, McCarthy S, Thompson G, Boerwinkle E, Utermann G: Relation of serum lipoprotein (a) concentration and apolipoprotein (a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med 322: 1494-1499, 1990.
23. Wiklund O, Angelin B, Olofsson SO, Eriksson M, Fager G, Berglund L, Boendjers G: Apolipoprotein (a) and ischaemic heart disease in familial hypercholesterolaemia. Lancet 335: 1360-1363, 1990.
24. Rosengren A, Wilhelmsen L, Eriksson E. Risberg B, Wedel H: Lipoprotein (a) and coronary heart disease: a prospective case control study in a general population sample of middle aged men. BMJ 301: 1248-1251, 1990.
25. Schaefer EJ, Lamon-Fava S, Jenner J, McNamara JR, Ordovas JM, Davis E, Abolafia JM, Lippel K, Levy RI: Lipoprotein (a) levels and risk of coronary heart disease in men: the Lipid Research Clinics Coronary Primary Prevention Trial. JAMA 271: 999-1003, 1994.
26. Wald NJ, Law M, Watt HC, Wu T, Bailey A, Johnson AM, Craig WY, Ledue TB, Haddow JE: Apolipoproteins and ischaemic heart disease: implications for screening. Lancet 343: 75-79, 1994.
27. Pavlidis N, Petris Ch, Briassoulis E, Klouvas G, Psilas C, Rempapis J, Petroutsos G' Clear evidence that long-term, low-dose tamoxifen treatment can induce occular toxicity. Cancer 69: 2961-2964, 1992.
28. Kalef-Ezra J, Glaros D, Klouvas G, Hatzikonstantinou J, Karantanas A, Siamopoulos KC, Pavlidis N: New evidence that tamoxifen does not induce osteoporosis: a nuclear activation analysis and absorptiometry study. Br J Radiology 65: 417-420, 1992.
29. Friediwald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 409-502, 1972.
30. Silberman SR, Armentrout MA, Vella FA, Saha AI: Macra (TM) Lp(a) for quantitation of human lipoprotein (a) by enzyme linked immunoassay (abstract). Clin Chem 36: 961, 1990.
31. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM: Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 325: 1196-1204, 1991.
32. Seishima M, Bisgaier CL, Davies SL, Glickman RM: Regulation of hepatic apoli-poprotein synthesis in the 17 a-ethinyl estradiol-treated rat. J Lipid Res 32: 941-951, 1991.
33. Soma M, Fumagalli R, Paoletti R, Meschia M, Carena Miani M, Crosignani P, Ghanem K, Gauhatz J, Morrisctt JD: Plasma Lp(a) concentration after oestrogen and progesterone in post-menopausal women (Letter). Lancet 337: 612, 1991
34. Soma M, Osnago-Gadda I, Paoletti R, Fumagalli R, Morisell JD, Meschia M, Crosignani P: The lowering of lipoproteiri(a) induced by estrogen plus progesterone replacement therapy in postmenopausal women. Arch Intern Med 153: 1462-1468, 1993.
35. Kim CJ, Jang HC, Cho DH, Min YK: Effects of hormone replacement therapy on lipoprotein (a) and lipids in postmenopausal women. Arterioscler Thromh 14: 275-281, 1994.
36. Lobo RA, Notelovitz M, Bernstein L, Khan FY, Ross RK, Paul WL: Lp(a) lipoprotein: Relationship to cardiovascular disease risk factors. exercise, and estrogen. Am J Obstet Gynecol 166; 1182-1190, 1992.
37. Nabulsi M, Folsom AR, White A, Patsch W, Heiss G, Wu KK, Szklo M: Association of hormone-replacemet therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 328: 1069-1075, 1993.
38. Hofmann SL, Eaton DL, Brown MS, McConathy WS, Goldstein SL,Hammer RE: Overexprcssion of human low density lipoprotein receptors leads to accelerated catabolism of Lp(a) lipoprotein in transgenic mice. J Clin Invest 85: 1542-1547, 1990.
39. Shewmon DA, Stock JL, Abusamra LC, Kristan MA, Baker S, Heiniluoma KM: Tamoxifen decreases lipoprotein (a) in patients with breast cancer. Metabolism 43: 531-532, 1994.
40. Shewmon Da, Stock JL, Heiniluoma KM, Arpano M, Ukena TR, Weale VW: Tamoxifen lowers Lp(a) in males with heart disease. Circulation 86: 1-338, 1992.
41. Skipski VP, Barclay M, Barclay RK, Fetzer VA, Good JJ, Archibald FM: Lipid composition of human serum lipoproteins. Biochem J 104: 340-352, 1967.
42. Stampfer MJ, Sacks FM, Salvini S, Wilett WC, Hennekens CH: A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 325: 373-381, 1991.
43. Castelli WP, Abbott RD, McNamara PM: Summary estimates of cholesterol used to predict coronary heart disease. Circulation 67: 730-734, 1983.
44. Pan QX, Liu P, Wang SC, Pan JT, Sun BY, Wu XY, Saltups A: The study of serum apoprotein levels as indicators for the severity of angiographically assessed coronary artery disease. Am J Clin Pathol 95: 597-600, 1991.
45. Ronnemaa T, Laakso M, Kallio V, Pyorala K, Marniemi J, Puukka P: Serum lipids, lipoproteins, and apolipoproteins and the excessive occurrence of coronary heart disease in non-insulin-dependent diabetic patients. Am J Epidemiol 130: 632-645, 1989.
46. Freedman DS, Srinivasan SR, Shear CL, Franklin FA Webber LS Berenson GS: The relation of apolipoproteins A-1 and B in children to parental myocardial infarction. N Engl J Med 315: 721-726, 1986.